AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Long-standing trade agreements have largely sheltered the pharmaceutical industry from tariffs but President Donald Trump's ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

Already reeling from years of market chaos, the announced departure of CBER chief Peter Marks sent a ripple across biopharma ...

A federal judge has dismissed Amgen’s lawsuit against Colorado’s Prescription Drug Affordability Board, allowing the state to move forward with setting price ceilings on prescription drugs, The Denver ...

Better-than-expected financial results in recent quarters have signaled an improved outlook, helping to sustain the rally.

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...